Effective August 13, 2021, Mr. Brian Leuthner has left OncoSec Medical Incorporated. Mr. Leuthner was appointed as Chief Operating Officer upon joining the Company in February 2021, and was serving as Interim Chief Executive Officer of the Company since June 24, 2021. Effective August 13, 2021, the Board of Directors of the Company established a Leadership Committee (the ‘Leadership Committee’) of members of the Board to lead the Company on an interim basis and until the Board appoints a Chief Executive Officer. The Leadership Committee consists of the following Board members: Dr. Margaret Dalesandro (Chair of the Board), Dr. Yuhang Zhao and Dr. Herbert Kim Lyerly. The Leadership Committee will report directly to and work with the Company’s Board. In connection with Mr. Leuthner’s departure, the Company and Mr. Leuthner entered into a separation agreement on August 13, 2021, providing for severance payments and benefits to Mr. Leuthner consistent with the terms of his existing offer letter with the Company, including a severance payment of $365,000, less tax withholdings, and reimbursement of COBRA premiums.